Ing. Filip Rázga, Ph.D.
Počet publikací: 73
2016
-
Quantitative assessment of the CD26+leukemic stem cell compartment in chronic myeloid leukemia: Patient-subgroups, prognostic impact, and technical aspects
Oncotarget, rok: 2016, ročník: 7, vydání: 22, DOI
2015
-
Can we predict resistance in CML? - a single center experience
Rok: 2015, druh: Konferenční abstrakty
2014
-
BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing
American Journal of Hematology, rok: 2014, ročník: 89, vydání: 10, DOI
-
Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry
Analytical Letters, rok: 2014, ročník: 47, vydání: 6, DOI
-
No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia
Hematological Oncology, rok: 2014, ročník: 32, vydání: 2, DOI
-
Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34+ cells of patients with de novo chronic myeloid leukemia
LEUKEMIA & LYMPHOMA, rok: 2014, ročník: 55, vydání: 8, DOI
2013
-
Are mutations in the IDH2 gene suitable molecular markers for MRD monitoring in AML patienst?
Rok: 2013, druh: Konferenční abstrakty
-
Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia with NPM1 mutations
Leukemia & Lymphoma, rok: 2013, ročník: 54, vydání: 5, DOI
-
Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
Leukemia & Lymphoma, rok: 2013, ročník: 54, vydání: 10, DOI
-
Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia.
Haematologica, rok: 2013, ročník: 98, vydání: 10, DOI